Anti leukaemia drug recognised with PM Prize for Innovation
The Australian Synchrotron has played a crucial role in the discovery of a new cancer drug for the treatment of leukaemia.
Showing 521 - 540 of 576 results
The Australian Synchrotron has played a crucial role in the discovery of a new cancer drug for the treatment of leukaemia.
Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.
In 2023 we’re celebrating the 70th Anniversary since Australia began developing our nation’s Australia’s nuclear capabilities.
ANSTO will be participating in a new Industrial Transformation Training Centre established and funded by the Australia Research Council to advance the use of bioactive ingredients in Australia.
ANSTO is collaborating on a project funded with an Australian Research Council linkage grant that will develop new materials and better systems for efficiently storing hydrogen gas.
ANSTO has almost seventy years of experience in advancing an understanding of the management of spent nuclear fuel and delivering safe and reliable forms for radioactive waste.
The IAEA is providing $1.3m over four years to implement a new, Australian-led patient-care project for the Asia and Pacific region
ANSTO provides access to specialised facilities and capabilities by application. Please ensure that you contact the relevant ANSTO scientist for advice before submitting a proposal.
Two approaches use existing low cost and low energy technologies to reuse stockpiled waste from mining operations - capturing carbon dioxide in the form of valuable carbonate minerals.
With a well-established portfolio of nuclear research and the operation of Australia's only nuclear reactor OPAL, ANSTO scientists conduct both fundamental and applied research on fuel for current, advanced, and future nuclear technology systems.
Project Bright, the construction of eight new beamlines at ANSTO’s Australian Synchrotron has reached a milestone by achieving ‘First Light’ for the new micro-computed tomography (MCT) beamline in late NovembeR.
A unique scientific capability comprising a single research platform for high-fidelity simulation, real-time dosimetry, and biological response data is available all from a neutron instrument.
Outstanding individuals and teams have been recognised for their outstanding work, innovation, excellence in the 2025 ANSTO Awards.